Sign In
3 Mar 2017 07:00
3 March 2017
Venn Life Sciences Holdings Plc
("Venn Life Sciences" or the "Company")
Year End Update
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations, today provides the following update.
2016 represented another year of strong growth for Venn with sales in excess of €18m (2015 €11m). The business finished 2016 with a strong cash position of €3m (€1.75m 30 June 2016). The strong momentum enjoyed by the business in 2016 has continued into 2017 todate, with new business contracts signed to the value €5.7m in the first two months of the year.
Enquiries:
Venn Life Sciences Holdings Plc | ||||
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 | |||
Davy (Nominated Adviser, ESM Adviser and Joint Broker) | ||||
Fergal Meegan / Matthew de Vere White (Corporate Finance) | Tel: +353 1 679 6363 | |||
| ||||
Hybridan LLP (Co-Broker) | ||||
Claire Louise Noyce | Tel: +44(0) 20 3764 2341 | |||
Walbrook PR Ltd | Tel: +44 (0) 20 7933 8787 or venn@walbrookpr.com | |||
Paul McManus | Mob: +44(0) 7980 541 893 | |||
Lianne Cawthorne | Mob: +44(0) 7584 391 303 | |||
About Venn Life Sciences:
Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects.
Follow the stocks
